Literature DB >> 16597658

T-cell recognition of glycolipids presented by CD1 proteins.

David C Young1, D Branch Moody.   

Abstract

The most well-known molecular paradigm of antigen recognition by T cells involves partial digestion of proteins to generate small peptides, which bind to major histocompatibility complex (MHC) proteins. Recent studies of CD1, an MHC class I homolog encoded outside the MHC, have revealed that it presents diverse glycolipids to T cells. The molecular mechanism for lipid antigen recognition involves insertion of the lipid portion of antigens into a hydrophobic groove to form CD1-lipid complexes, which contact T-cell receptors (TCRs). Here, we examine the known antigen structures presented by CD1, the majority of which have sugar moieties that are capable of interacting with TCRs. Recognition of carbohydrate epitopes is precise, and lipid-reactive T cells alter systemic immune responses in models of infectious and autoimmune disease. These findings provide a previously unrecognized mechanism by which the cellular immune system can recognize alterations in many types of carbohydrate structures.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16597658     DOI: 10.1093/glycob/cwj111

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  20 in total

1.  Gaucher disease gene GBA functions in immune regulation.

Authors:  Jun Liu; Stephanie Halene; Mei Yang; Jameel Iqbal; Ruhua Yang; Wajahat Z Mehal; Wei-Lien Chuang; Dhanpat Jain; Tony Yuen; Li Sun; Mone Zaidi; Pramod K Mistry
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

2.  Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.

Authors:  Roger S Riley; David Williams; Micaela Ross; Shawn Zhao; Alden Chesney; Bradly D Clark; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 3.  Lipidomic profiling of model organisms and the world's major pathogens.

Authors:  Emilie Layre; D Branch Moody
Journal:  Biochimie       Date:  2012-08-23       Impact factor: 4.079

Review 4.  Orchestration of invariant natural killer T cell development by E and Id proteins.

Authors:  Sumedha Roy; Yuan Zhuang
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

5.  CD1a and MHC class I follow a similar endocytic recycling pathway.

Authors:  Duarte C Barral; Marco Cavallari; Peter J McCormick; Salil Garg; Anthony I Magee; Juan S Bonifacino; Gennaro De Libero; Michael B Brenner
Journal:  Traffic       Date:  2008-06-28       Impact factor: 6.215

6.  Synthesis of dideoxymycobactin antigens presented by CD1a reveals T cell fine specificity for natural lipopeptide structures.

Authors:  David C Young; Anne Kasmar; Garrett Moraski; Tan-Yun Cheng; Andrew J Walz; Jingdan Hu; Yanping Xu; Gregory W Endres; Adam Uzieblo; Dirk Zajonc; Catherine E Costello; Marvin J Miller; D Branch Moody
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

7.  Human T cell response to CD1a and contact dermatitis allergens in botanical extracts and commercial skin care products.

Authors:  Sarah Nicolai; Marcin Wegrecki; Tan-Yun Cheng; Elvire A Bourgeois; Rachel N Cotton; Jacob A Mayfield; Gwennaëlle C Monnot; Jérôme Le Nours; Ildiko Van Rhijn; Jamie Rossjohn; D Branch Moody; Annemieke de Jong
Journal:  Sci Immunol       Date:  2020-01-03

Review 8.  Research and development of new tuberculosis vaccines: a review.

Authors:  Lewis K Schrager; Rebecca C Harris; Johan Vekemans
Journal:  F1000Res       Date:  2018-11-01

Review 9.  Evolutionarily conserved amino acids that control TCR-MHC interaction.

Authors:  Philippa Marrack; James P Scott-Browne; Shaodong Dai; Laurent Gapin; John W Kappler
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

Review 10.  Nonprotein structures from mycobacteria: emerging actors for tuberculosis control.

Authors:  Luz M Lopez-Marin
Journal:  Clin Dev Immunol       Date:  2012-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.